Lv1
70 积分 2025-10-29 加入
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
7小时前
已完结
Innovations in the classification of soft tissue tumors
5个月前
已完结
复发转移性宫颈癌诊疗指南（2025版）
6个月前
已完结
Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series
8个月前
已完结
Safety and Efficacy of Elranatamab in Patients with Daratumumab Relapsed and/or Refractory Immunoglobulin Light Chain Amyloidosis
8个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
8个月前
已完结
皖公网安备34019202002308
